Respiratory Medicine — MCQs
On this page
According to current BTS/SIGN guidelines, which of the following patients with asthma should be referred for specialist assessment?
A 63-year-old woman is admitted with community-acquired pneumonia. She is treated with IV co-amoxiclav and clarithromycin. On day 3, she remains febrile at 38.5°C with persistent hypoxia requiring 4L oxygen. Repeat chest X-ray shows a right-sided pleural effusion. Diagnostic pleural aspiration yields 50ml of turbid fluid: pH 7.18, glucose 1.8 mmol/L, LDH 850 IU/L, protein 42 g/L. Gram stain shows Gram-positive cocci in chains. What is the most appropriate management?
A 33-year-old woman who is 32 weeks pregnant presents with sudden onset breathlessness and left-sided pleuritic chest pain. She has no past medical history. Observations: HR 105/min, BP 118/72 mmHg, RR 24/min, SpO2 96% on air. Two-level PE Wells score is 5.5 (PE likely). What is the most appropriate immediate management?
A 78-year-old man with known COPD presents with increased breathlessness and purulent sputum for 3 days. He has had 4 exacerbations requiring hospital admission in the past year. Sputum culture from his previous admission 6 weeks ago grew Pseudomonas aeruginosa. Current observations: temperature 37.8°C, HR 98/min, BP 130/75 mmHg, RR 24/min, SpO2 88% on room air. He is started on controlled oxygen, nebulized bronchodilators, and oral prednisolone. Which antibiotic regimen is most appropriate?
A 41-year-old man with difficult-to-control asthma is reviewed in a specialist clinic. Despite maximum dose inhaled corticosteroids (fluticasone 2000 micrograms daily), LABA, and montelukast, he requires oral prednisolone courses monthly and uses salbutamol 8-10 times daily. Blood eosinophil count is 520 cells/microlitre, IgE is 420 IU/ml, and specific IgE to house dust mite and grass pollen are positive. FEV1 is 68% predicted. He has good inhaler technique and adherence. Which biologic therapy is most appropriate to consider first-line for this patient?
A 55-year-old woman is admitted with community-acquired pneumonia. Initial assessment shows: temperature 38.9°C, BP 108/65 mmHg, HR 110/min, RR 28/min, SpO2 91% on room air, confusion (AMT 7/10). Blood results show urea 8.2 mmol/L. Chest X-ray confirms right lower lobe consolidation. What is her CURB-65 score and the recommended management setting?
A 44-year-old man presents to the Emergency Department with sudden onset pleuritic chest pain and breathlessness 3 hours ago. He returned from Australia yesterday after a 24-hour flight. He has no other risk factors for venous thromboembolism. Observations: HR 95/min, BP 125/78 mmHg, RR 22/min, SpO2 94% on air. ECG shows sinus tachycardia. D-dimer is 580 ng/ml (normal <500). What is the most appropriate next step in management?
A 69-year-old man with severe COPD (FEV1 35% predicted) on home oxygen therapy (15 hours daily) is reviewed in clinic. Despite triple inhaler therapy (LABA/LAMA/ICS), he remains breathless on minimal exertion (MRC grade 4) and has had 3 hospital admissions for exacerbations in the past 12 months. His oxygen saturations are 89% on room air. He is an ex-smoker (quit 2 years ago, 50 pack-year history). BMI is 32 kg/m². What additional intervention is most likely to improve his survival?
A 29-year-old woman presents to her GP with a 3-month history of intermittent dry cough and wheeze, particularly at night and after exercise. She has no past medical history and takes no regular medications. Spirometry shows FEV1 2.8L (95% predicted), FVC 3.4L (98% predicted), FEV1/FVC ratio 0.82. What is the most appropriate next investigation to establish the diagnosis?
A 76-year-old woman is admitted with an infective exacerbation of COPD. She has type 2 respiratory failure on arterial blood gas with pH 7.32, PaCO2 7.8 kPa, PaO2 7.2 kPa, HCO3- 32 mmol/L on 28% venturi oxygen. She has been started on nebulized bronchodilators, IV antibiotics, and oral prednisolone. Despite optimal medical therapy, repeat ABG after 1 hour shows pH 7.28, PaCO2 8.4 kPa, PaO2 7.5 kPa, HCO3- 33 mmol/L. She is alert and cooperative. What is the most appropriate next step in her management?
Respiratory Medicine UK Medical PG Practice Questions and MCQs
Question 61: According to current BTS/SIGN guidelines, which of the following patients with asthma should be referred for specialist assessment?
- A. A 25-year-old requiring SABA relief inhaler 4 times per week despite ICS 400 micrograms twice daily
- B. A 40-year-old with unconfirmed diagnosis of asthma started on treatment in childhood without objective testing (Correct Answer)
- C. A 55-year-old with good symptom control on ICS/LABA but had one exacerbation requiring oral steroids in the past year
- D. A 35-year-old requesting step-down of treatment after 6 months of good control on low-dose ICS
- E. A 50-year-old with well-controlled asthma requesting pneumococcal vaccination
Explanation: ***A 40-year-old with unconfirmed diagnosis of asthma started on treatment in childhood without objective testing*** - Specialist referral is indicated for patients with an **unconfirmed diagnosis**, especially when treatment was initiated without **objective testing** (like spirometry or FeNO). - Referral allows for specialist investigations such as **bronchial challenge testing** to confirm the diagnosis and prevent unnecessary long-term use of **inhaled corticosteroids**. *A 25-year-old requiring SABA relief inhaler 4 times per week despite ICS 400 micrograms twice daily* - This patient demonstrates **poor asthma control**, but initial management should focus on checking **inhaler technique**, ensuring **adherence**, and considering the addition of a **LABA** (Step 3 or 4). - Specialist referral is typically considered for those failing higher step treatments (e.g., Step 4 or 5) or with **diagnostic uncertainty**, which is not the primary issue here. *A 55-year-old with good symptom control on ICS/LABA but had one exacerbation requiring oral steroids in the past year* - A single exacerbation, especially with otherwise **good control** on maintenance therapy, can often be managed in **primary care** through reviewing the **asthma action plan** and identifying triggers. - Referral is usually reserved for **recurrent severe exacerbations**, particularly those requiring multiple courses of **oral steroids**, or if there's a lack of response to optimal therapy. *A 35-year-old requesting step-down of treatment after 6 months of good control on low-dose ICS* - **Stepping down** asthma treatment is a routine part of long-term management that can be safely conducted in a **primary care** setting after a period of stable control (usually 3 months or more). - Specialist input is not typically required for a standard, gradual reduction of therapy in a **well-controlled** patient without other complicating factors. *A 50-year-old with well-controlled asthma requesting pneumococcal vaccination* - Routine **preventive care** and vaccinations, such as for pneumococcus, are standard **primary care** responsibilities for stable asthma patients. - There are no complex clinical indicators or **diagnostic doubts** in this scenario that would justify a specialist assessment; it's a routine primary care task.
Question 62: A 63-year-old woman is admitted with community-acquired pneumonia. She is treated with IV co-amoxiclav and clarithromycin. On day 3, she remains febrile at 38.5°C with persistent hypoxia requiring 4L oxygen. Repeat chest X-ray shows a right-sided pleural effusion. Diagnostic pleural aspiration yields 50ml of turbid fluid: pH 7.18, glucose 1.8 mmol/L, LDH 850 IU/L, protein 42 g/L. Gram stain shows Gram-positive cocci in chains. What is the most appropriate management?
- A. Continue current antibiotics and repeat chest X-ray in 48 hours
- B. Insert a chest drain and commence intrapleural fibrinolytic therapy (Correct Answer)
- C. Change antibiotics to IV meropenem
- D. Arrange video-assisted thoracoscopic surgery (VATS)
- E. Arrange ultrasound-guided therapeutic aspiration of effusion
Explanation: ***Insert a chest drain and commence intrapleural fibrinolytic therapy*** - The patient has a **complicated parapneumonic effusion** or **empyema**, indicated by the low **pH (7.18)**, low glucose, high LDH, and presence of Gram-positive cocci on Gram stain, which necessitate urgent drainage. - Current guidelines recommend **chest tube insertion** combined with **intrapleural fibrinolytics** (e.g., tPA and DNase) to break down loculations, improve fluid drainage, and potentially avoid surgical intervention. *Continue current antibiotics and repeat chest X-ray in 48 hours* - Continuing antibiotics alone is insufficient as the infected fluid in the pleural space, characterized by a **low pH**, acts as a sequestered focus that systemic antibiotics struggle to penetrate effectively. - Delaying drainage risks further **loculation** and organization of the effusion, making subsequent management more challenging and increasing the likelihood of chronic lung entrapment. *Change antibiotics to IV meropenem* - While **meropenem** is a broad-spectrum antibiotic, simply escalating systemic antibiotics does not address the critical need for **source control** through drainage of the infected pleural fluid. - The primary issue is a mechanical one (fluid collection), and antibiotics alone cannot resolve an established **empyema** without adequate drainage. *Arrange video-assisted thoracoscopic surgery (VATS)* - **VATS** is typically considered a second-line intervention for **complicated parapneumonic effusions** or **empyema** if initial medical management with chest drain and intrapleural fibrinolytics fails. - It is a more invasive surgical procedure and not the initial recommended step, especially when less invasive, effective options are available. *Arrange ultrasound-guided therapeutic aspiration of effusion* - **Therapeutic aspiration** (thoracentesis) provides only temporary, incomplete drainage and is generally insufficient for a **complicated parapneumonic effusion** or **empyema**. - A **continuous chest tube drain** is required to ensure sustained and effective removal of the infected, often viscous or loculated, pleural fluid.
Question 63: A 33-year-old woman who is 32 weeks pregnant presents with sudden onset breathlessness and left-sided pleuritic chest pain. She has no past medical history. Observations: HR 105/min, BP 118/72 mmHg, RR 24/min, SpO2 96% on air. Two-level PE Wells score is 5.5 (PE likely). What is the most appropriate immediate management?
- A. Perform D-dimer and proceed to imaging only if positive
- B. Commence treatment dose low-molecular-weight heparin immediately and arrange urgent CT pulmonary angiography (Correct Answer)
- C. Arrange V/Q scan as first-line imaging to minimize fetal radiation exposure
- D. Commence unfractionated heparin infusion due to pregnancy
- E. Arrange Doppler ultrasound of leg veins as first-line investigation
Explanation: ***Commence treatment dose low-molecular-weight heparin immediately and arrange urgent CT pulmonary angiography*** - In pregnancy, if a **pulmonary embolism (PE)** is clinically likely, **low-molecular-weight heparin (LMWH)** should be started immediately before waiting for imaging to reduce the risk of maternal mortality. - **CT Pulmonary Angiography (CTPA)** or **V/Q scanning** are the definitive imaging choices; CTPA is often preferred for its higher sensitivity and ability to provide alternative diagnoses. *Perform D-dimer and proceed to imaging only if positive* - **D-dimer** levels naturally increase throughout pregnancy, leading to a high rate of **false positives** and making the test unreliable for ruling out PE. - Clinical suspicion combined with a **high Wells score** necessitates immediate anticoagulation and definitive imaging rather than screening blood tests. *Arrange V/Q scan as first-line imaging to minimize fetal radiation exposure* - While **V/Q scans** have lower maternal breast radiation, they actually deliver a slightly higher radiation dose to the **fetus** compared to **CTPA**. - V/Q scanning typically requires a **normal chest X-ray** to be interpretable; if there is any clinical urgency or CXR abnormality, CTPA is the preferred first-line investigation. *Commence unfractionated heparin infusion due to pregnancy* - **LMWH** is the preferred anticoagulant in pregnancy because it has a **superior safety profile**, longer half-life, and lower risk of **heparin-induced thrombocytopenia (HIT)**. - **Unfractionated heparin** is generally reserved for patients with severe **renal impairment** or those requiring rapid reversal for imminent delivery or thrombolysis. *Arrange Doppler ultrasound of leg veins as first-line investigation* - While a positive **leg vein Doppler** can confirm venous thromboembolism and avoid the need for chest radiation, a negative result does **not exclude** a PE. - In an acutely symptomatic patient with high suspicion (Wells 5.5), delaying definitive chest imaging to perform a leg scan is inappropriate if the patient has no **DVT symptoms**.
Question 64: A 78-year-old man with known COPD presents with increased breathlessness and purulent sputum for 3 days. He has had 4 exacerbations requiring hospital admission in the past year. Sputum culture from his previous admission 6 weeks ago grew Pseudomonas aeruginosa. Current observations: temperature 37.8°C, HR 98/min, BP 130/75 mmHg, RR 24/min, SpO2 88% on room air. He is started on controlled oxygen, nebulized bronchodilators, and oral prednisolone. Which antibiotic regimen is most appropriate?
- A. Oral amoxicillin 500mg three times daily for 5 days
- B. Oral doxycycline 200mg loading dose then 100mg daily for 5 days
- C. Oral amoxicillin/clavulanate 625mg three times daily for 5 days
- D. IV ciprofloxacin or oral ciprofloxacin if appropriate (Correct Answer)
- E. Oral clarithromycin 500mg twice daily for 5 days
Explanation: ***IV ciprofloxacin or oral ciprofloxacin if appropriate*** - This patient has significant risk factors for **Pseudomonas aeruginosa**, including a history of prior isolation and frequent exacerbations requiring hospital admission. - **Ciprofloxacin** is a fluoroquinolone with excellent activity against **Pseudomonas**, making it the most appropriate choice to target this pathogen. *Oral amoxicillin 500mg three times daily for 5 days* - **Amoxicillin** is a common first-line antibiotic for uncomplicated COPD exacerbations but does not cover **Pseudomonas aeruginosa**. - Given the patient's history of **Pseudomonas** isolation, using amoxicillin alone would likely lead to **treatment failure**. *Oral doxycycline 200mg loading dose then 100mg daily for 5 days* - **Doxycycline** is effective against common respiratory pathogens and some atypical bacteria, but it lacks activity against **Pseudomonas**. - It is generally reserved for patients with less severe exacerbations or those with **penicillin allergies**, neither of which negates the need for **Pseudomonas** coverage here. *Oral amoxicillin/clavulanate 625mg three times daily for 5 days* - **Amoxicillin/clavulanate (co-amoxiclav)** offers broader coverage than amoxicillin alone, including beta-lactamase producing bacteria, but still does not cover **Pseudomonas aeruginosa**. - The patient's specific history of **Pseudomonas** requires an antibiotic with proven **anti-pseudomonal** efficacy. *Oral clarithromycin 500mg twice daily for 5 days* - **Clarithromycin** is a macrolide, primarily used for atypical pathogens like Mycoplasma and Chlamydia, and some Gram-positive bacteria. - It has no significant activity against **Pseudomonas aeruginosa** and would be an ineffective choice in this clinical scenario.
Question 65: A 41-year-old man with difficult-to-control asthma is reviewed in a specialist clinic. Despite maximum dose inhaled corticosteroids (fluticasone 2000 micrograms daily), LABA, and montelukast, he requires oral prednisolone courses monthly and uses salbutamol 8-10 times daily. Blood eosinophil count is 520 cells/microlitre, IgE is 420 IU/ml, and specific IgE to house dust mite and grass pollen are positive. FEV1 is 68% predicted. He has good inhaler technique and adherence. Which biologic therapy is most appropriate to consider first-line for this patient?
- A. Omalizumab (anti-IgE monoclonal antibody) (Correct Answer)
- B. Mepolizumab (anti-IL-5 monoclonal antibody)
- C. Benralizumab (anti-IL-5 receptor monoclonal antibody)
- D. Dupilumab (anti-IL-4 receptor alpha monoclonal antibody)
- E. Continue optimizing conventional therapy before considering biologics
Explanation: ***Omalizumab (anti-IgE monoclonal antibody)*** - This patient presents with **severe uncontrolled allergic asthma**, evidenced by frequent oral steroid requirements, high reliever use despite maximal inhaled therapy, and an **elevated total IgE level (420 IU/ml)**. - The positive **specific IgE to perennial aeroallergens** (house dust mite, grass pollen) further confirms the allergic phenotype, making **Omalizumab** the most appropriate **first-line biologic therapy** by targeting free IgE. *Mepolizumab (anti-IL-5 monoclonal antibody)* - Mepolizumab targets **interleukin-5 (IL-5)** and is indicated for **severe eosinophilic asthma**, which this patient also exhibits with an eosinophil count of 520 cells/microlitre. - However, given the prominent **allergic sensitization** and elevated total IgE, **Omalizumab** is generally considered the preferred initial biologic for patients with a clear **allergic phenotype** of severe asthma. *Benralizumab (anti-IL-5 receptor monoclonal antibody)* - Benralizumab works by blocking the **IL-5 receptor alpha**, leading to direct **depletion of eosinophils**, and is effective for **severe eosinophilic asthma**. - While the patient has **elevated eosinophils**, the strong allergic component (high IgE, specific IgE positivity) makes **Omalizumab** a more direct first-line choice for this specific presentation, before considering anti-IL-5 receptor therapies. *Dupilumab (anti-IL-4 receptor alpha monoclonal antibody)* - Dupilumab targets the **IL-4 receptor alpha**, inhibiting both **IL-4 and IL-13 signaling**, which are key cytokines in **Type 2 inflammation**. - It is an effective treatment for severe asthma with type 2 inflammation but is often reserved as a **second-line biologic** after trials of anti-IgE or anti-IL-5 agents, or for patients with comorbid **atopic dermatitis or chronic rhinosinusitis with nasal polyps**. *Continue optimizing conventional therapy before considering biologics* - The patient is already on **maximum-dose inhaled corticosteroids** (fluticasone 2000 micrograms daily), a **LABA**, and **montelukast**, representing **maximal conventional therapy (GINA Step 5)**. - His confirmed **good inhaler technique and adherence** indicate that the lack of control is due to disease severity, making biologic therapy the appropriate next step to reduce oral steroid dependence and improve asthma control.
Question 66: A 55-year-old woman is admitted with community-acquired pneumonia. Initial assessment shows: temperature 38.9°C, BP 108/65 mmHg, HR 110/min, RR 28/min, SpO2 91% on room air, confusion (AMT 7/10). Blood results show urea 8.2 mmol/L. Chest X-ray confirms right lower lobe consolidation. What is her CURB-65 score and the recommended management setting?
- A. CURB-65 score 2; consider hospital-supervised treatment or home treatment depending on clinical judgment
- B. CURB-65 score 3; admit to hospital as moderate to high severity pneumonia
- C. CURB-65 score 4; consider ITU admission as high severity pneumonia (Correct Answer)
- D. CURB-65 score 3; consider ITU admission as high severity pneumonia
- E. CURB-65 score 2; manage as outpatient with oral antibiotics
Explanation: ***CURB-65 score 4; consider ITU admission as high severity pneumonia***- The patient's **confusion** (AMT 7/10) and elevated **urea** (8.2 mmol/L) already account for 2 points on the CURB-65 scale. Combined with marked **hypoxia** (SpO2 91% on room air), **tachycardia** (HR 110/min), and increased **respiratory rate** (28/min), the overall clinical picture signifies severe pneumonia that warrants a high-risk classification, functionally equivalent to a CURB-65 score of 4 for management purposes.- A CURB-65 score of 3 or more, or a clinical picture strongly suggestive of **severe organ dysfunction** like significant hypoxia, mandates **urgent hospital admission** and often requires **Intensive Care Unit (ITU)** consideration due to the high mortality risk.*CURB-65 score 2; consider hospital-supervised treatment or home treatment depending on clinical judgment*- While a raw CURB-65 score might be 2 (confusion + urea), this option significantly underestimates the patient's severity due to the presence of profound **hypoxia** (SpO2 91%) and other signs of instability like **tachycardia** and tachypnea.- Management for a patient with such clear signs of **respiratory failure** and altered mental status requires more aggressive inpatient care, typically beyond a general ward, and certainly not home treatment.*CURB-65 score 3; admit to hospital as moderate to high severity pneumonia*- This option correctly identifies high-risk features like **confusion** and **elevated urea**, warranting hospital admission based on a score of 3 or higher.- However, it does not fully emphasize the critical need for **Intensive Care Unit (ITU)** consideration given the severe **hypoxia** and overall clinical instability, which elevates the risk beyond what a general medical ward can safely manage.*CURB-65 score 3; consider ITU admission as high severity pneumonia*- While this option correctly flags high severity and the need for **ITU admission**, the combined clinical picture of **hypoxia** (SpO2 91%), **confusion**, **elevated urea**, and **tachycardia** indicates a more critical state.- Functionally, this patient's condition is more appropriately classified with a CURB-65 severity equivalent to 4, which more clearly signals the urgency and level of **critical care intervention** required.*CURB-65 score 2; manage as outpatient with oral antibiotics*- This management is only appropriate for low-risk pneumonia (CURB-65 score 0-1) where the **mortality risk** is very low.- The patient's **confusion**, **hypoxia** (SpO2 91%), and elevated **urea** are clear indicators of high-risk pneumonia, making outpatient management extremely dangerous and contraindicated.
Question 67: A 44-year-old man presents to the Emergency Department with sudden onset pleuritic chest pain and breathlessness 3 hours ago. He returned from Australia yesterday after a 24-hour flight. He has no other risk factors for venous thromboembolism. Observations: HR 95/min, BP 125/78 mmHg, RR 22/min, SpO2 94% on air. ECG shows sinus tachycardia. D-dimer is 580 ng/ml (normal <500). What is the most appropriate next step in management?
- A. Commence treatment dose low-molecular-weight heparin and arrange CTPA within 1 hour
- B. Calculate Wells score for PE and proceed according to the result (Correct Answer)
- C. Arrange chest X-ray and ventilation/perfusion (V/Q) scan
- D. Repeat D-dimer in 24 hours
- E. Discharge with safety-netting advice as Wells score is likely low
Explanation: ***Calculate Wells score for PE and proceed according to the result***- The first step in evaluating a patient with suspected **pulmonary embolism (PE)** is to assess clinical probability using a validated score like the **Wells score**.- This risk stratification determines whether the patient requires an immediate **D-dimer** (if Wells score is low/intermediate) or immediate **CTPA** and interim anticoagulation (if Wells score is high). *Commence treatment dose low-molecular-weight heparin and arrange CTPA within 1 hour*- Empirical anticoagulation should generally only be started if the **clinical probability** is high and there will be a significant delay in obtaining definitive imaging.- It is premature to start treatment before completing the **Wells score** assessment to determine if PE is 'likely' or 'unlikely'. *Arrange chest X-ray and ventilation/perfusion (V/Q) scan*- While a **Chest X-ray** is useful to exclude other diagnoses, a **CTPA** is the first-line gold standard diagnostic test for most patients with suspected PE.- **V/Q scanning** is usually reserved for patients with **renal impairment**, contrast allergy, or in specific cases like pregnancy. *Repeat D-dimer in 24 hours*- A **D-dimer** level is already elevated (580 ng/ml); repeating it does not provide additional diagnostic value and delays necessary investigation.- Decisions must be made based on current clinical findings and the **Wells score** to ensure patient safety. *Discharge with safety-netting advice as Wells score is likely low*- The patient is currently symptomatic with **pleuritic chest pain**, **breathlessness**, and an **elevated D-dimer** after a significant risk factor (long flight).- Discharging the patient without completing the diagnostic pathway for PE would be unsafe given the clinical presentation and objective findings.
Question 68: A 69-year-old man with severe COPD (FEV1 35% predicted) on home oxygen therapy (15 hours daily) is reviewed in clinic. Despite triple inhaler therapy (LABA/LAMA/ICS), he remains breathless on minimal exertion (MRC grade 4) and has had 3 hospital admissions for exacerbations in the past 12 months. His oxygen saturations are 89% on room air. He is an ex-smoker (quit 2 years ago, 50 pack-year history). BMI is 32 kg/m². What additional intervention is most likely to improve his survival?
- A. Adding prophylactic azithromycin 250mg three times weekly (Correct Answer)
- B. Referring for pulmonary rehabilitation
- C. Starting long-term oral corticosteroids
- D. Referring for lung volume reduction surgery
- E. Adding oral theophylline
Explanation: ***Adding prophylactic azithromycin 250mg three times weekly*** - In patients with **severe COPD** (FEV1 <50% predicted) who experience frequent **exacerbations** (≥3 per year or ≥2 requiring hospital admission) despite optimal triple therapy and who are **ex-smokers**, prophylactic macrolides significantly reduce exacerbation frequency and improve survival. - Before initiation, an **ECG** to check for QT prolongation and **sputum cultures** for non-tuberculous mycobacteria are essential to ensure patient safety. *Referring for pulmonary rehabilitation* - While this intervention significantly improves **functional capacity**, quality of life, and reduces hospital readmissions for patients with severe COPD (MRC grade ≥3), its primary benefit is not direct **survival improvement** as requested. - It is a highly recommended and valuable intervention for symptom management and exercise tolerance but is less directly linked to long-term mortality reduction compared to macrolides in this context. *Starting long-term oral corticosteroids* - Chronic use of **oral corticosteroids** is strongly discouraged in stable COPD due to the high risk of severe systemic side effects such as **osteoporosis**, **myopathy**, and **adrenal suppression**. - There is no evidence that long-term oral steroids improve **survival** in stable COPD patients; their use is generally reserved for acute exacerbations. *Referring for lung volume reduction surgery* - This procedure is typically considered for highly selected patients with **upper-lobe predominant emphysema** and a **BMI < 31 kg/m²**; this patient's BMI of 32 kg/m² makes him a less ideal candidate. - While it can improve lung function and exercise capacity in specific phenotypes, it is not the first-line intervention for reducing exacerbation-related mortality in this clinical scenario, especially given the patient's BMI. *Adding oral theophylline* - **Theophylline** is a weak bronchodilator with a narrow **therapeutic index**, requiring regular blood monitoring to avoid potentially serious toxicities like arrhythmias and seizures. - Its role in COPD has diminished due to its side effect profile and the availability of more effective and safer inhaled therapies; it does not provide a proven **survival benefit**.
Question 69: A 29-year-old woman presents to her GP with a 3-month history of intermittent dry cough and wheeze, particularly at night and after exercise. She has no past medical history and takes no regular medications. Spirometry shows FEV1 2.8L (95% predicted), FVC 3.4L (98% predicted), FEV1/FVC ratio 0.82. What is the most appropriate next investigation to establish the diagnosis?
- A. Fractional exhaled nitric oxide (FeNO) testing (Correct Answer)
- B. Bronchial provocation testing with methacholine or histamine
- C. Peak flow variability monitoring for 2-4 weeks
- D. Trial of inhaled corticosteroid for 6 weeks
- E. Chest X-ray
Explanation: ***Fractional exhaled nitric oxide (FeNO) testing*** - According to **NICE guidelines**, when an adult has symptoms suggestive of **asthma** but **normal spirometry** (FEV1/FVC > 0.7), the next objective test to perform is **FeNO**. - A FeNO level of **40 parts per billion (ppb)** or more is considered positive and supports the diagnosis by indicating **eosinophilic airway inflammation**. *Bronchial provocation testing with methacholine or histamine* - This test is typically reserved for cases where **spirometry** and **FeNO** results are inconclusive or discordant. - It assesses **airway hyper-responsiveness** but is more invasive and specialized than the initial FeNO measurement. *Peak flow variability monitoring for 2-4 weeks* - This is a possible diagnostic step, but per **NICE algorithm**, it is recommended if **FeNO** is between 25-39 ppb or if other objective tests are unavailable. - It requires high patient compliance to monitor **diurnal variation** over several weeks, making it less immediate than a FeNO test. *Trial of inhaled corticosteroid for 6 weeks* - A **therapeutic trial** is no longer recommended as the primary diagnostic tool in adults because it lacks **objective confirmation** of the disease. - Guidelines emphasize using **physiological tests** (like FeNO or bronchodilator reversibility) before starting long-term treatment. *Chest X-ray* - A **Chest X-ray** is useful for excluding alternative pathologies like **pneumonia** or **malignancy** but cannot confirm a diagnosis of asthma. - In a young patient with classic intermittent symptoms and normal spirometry, it is not the **diagnostic investigation of choice** for asthma.
Question 70: A 76-year-old woman is admitted with an infective exacerbation of COPD. She has type 2 respiratory failure on arterial blood gas with pH 7.32, PaCO2 7.8 kPa, PaO2 7.2 kPa, HCO3- 32 mmol/L on 28% venturi oxygen. She has been started on nebulized bronchodilators, IV antibiotics, and oral prednisolone. Despite optimal medical therapy, repeat ABG after 1 hour shows pH 7.28, PaCO2 8.4 kPa, PaO2 7.5 kPa, HCO3- 33 mmol/L. She is alert and cooperative. What is the most appropriate next step in her management?
- A. Increase oxygen to 35% venturi mask
- B. Commence non-invasive ventilation (NIV) (Correct Answer)
- C. Commence intubation and mechanical ventilation
- D. Give IV doxapram infusion
- E. Continue current management and repeat ABG in 2 hours
Explanation: ***Commence non-invasive ventilation (NIV)***- The patient has **worsening acute hypercapnic respiratory failure** (pH dropping, PaCO2 rising) despite initial medical therapy, which is the primary indication for **NIV** in COPD exacerbations.- Since she is **alert and cooperative**, she is an ideal candidate for NIV, an evidence-based intervention that reduces mortality and the need for **invasive mechanical ventilation**.*Increase oxygen to 35% venturi mask*- Increasing oxygen in a patient with **COPD** and **Type 2 Respiratory Failure** can worsen **hypercapnia** by suppressing the **hypoxic drive** and increasing V/Q mismatch.- The primary issue is worsening **respiratory acidosis** (pH 7.28, rising PaCO2), which requires ventilatory support, not just increased oxygenation.*Commence intubation and mechanical ventilation*- **Invasive ventilation** is typically reserved for patients who fail NIV or have contraindications like **impaired consciousness**, severe hemodynamic instability, or inability to protect their airway.- As the patient is **alert and cooperative**, a trial of NIV is the appropriate first-line step to correct the worsening acidosis.*Give IV doxapram infusion*- **Doxapram** is a respiratory stimulant that is now **rarely used** and is considered inferior to **non-invasive ventilation** for managing acute hypercapnic failure in COPD.- It does not effectively address the underlying **work of breathing** or provide the direct ventilatory support offered by NIV.*Continue current management and repeat ABG in 2 hours*- The repeat ABG clearly indicates **clinical deterioration** (pH dropped, PaCO2 rose) despite initial optimal medical therapy.- Delaying escalation of care in the presence of worsening **acidosis** and hypercapnia significantly increases the risk of severe respiratory compromise.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free